THERAPEUTICS
Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder
| The first 150 words of the full text of this article appear below. |
Does switching to aripiprazole from olanzapine improve metabolic status in overweight people with schizophrenia or schizoaffective disorder?
Patients with schizophrenia or schizoaffective disorder (DSM-IV-TR) treated with olanzapine only (10–20 mg/day for 1–24 months). Inclusion criteria: body mass index
27; Clinical Global Impressions-Severity score
4. Main exclusion criteria: other axis I disorder; diabetes; neurological condition or mental retardation; suicide risk; alcohol or drug dependence or electroconvulsive therapy 3 months prior to study; previous failure to respond to aripiprazole; clinically significant ECG, blood result or vital sign; pregnant, breastfeeding or not reliably using contraception for the duration of the study plus 4 weeks after study completion.
Multinational (countries not stated); recruitment 30 March 2004 to 8 August 2006.
Switch to aripiprazole (n = 88) or continued olanzapine (n = 85) for 16 weeks. Switch participants received up to 15 mg/day aripiprazole across 2 weeks while decreasing olanzapine dose to nil, then 15
Concord Centre for Cardiometabolic Health in Psychosis and The Brain and Mind Research Institute, University of Sydney, Australia
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
